Ascletis Pharma Inc (2VJ) — Cash Flow-to-Debt Ratio
Ascletis Pharma Inc (2VJ) has a Cash Flow-to-Debt Ratio of -0.37x as of June 2023, meaning its operating cash flow of €-33.98 Million could theoretically repay 0% of its total liabilities (€90.79 Million) in one year. Explore Ascletis Pharma Inc operating cash flow efficiency to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ascletis Pharma Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Ascletis Pharma Inc across 10 annual periods. Also explore Ascletis Pharma Inc balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Ascletis Pharma Inc (2016–2025)
Year-by-year debt coverage analysis for Ascletis Pharma Inc. For market capitalisation and broader financial context, see 2VJ market cap.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | €-416.78 Million | €132.26 Million | ▼ -46.1% |
| 2024 | -2.16x | €-341.58 Million | €158.41 Million | ▼ -43.5% |
| 2023 | -1.50x | €-223.79 Million | €148.94 Million | ▼ -23.6% |
| 2022 | -1.22x | €-142.45 Million | €117.16 Million | ▲ +16.5% |
| 2021 | -1.46x | €-146.93 Million | €100.89 Million | ▼ -46.5% |
| 2020 | -0.99x | €-84.91 Million | €85.42 Million | ▼ -36.6% |
| 2019 | -0.73x | €-74.34 Million | €102.17 Million | ▲ +24.5% |
| 2018 | -0.96x | €-96.59 Million | €100.19 Million | ▲ +40.9% |
| 2017 | -1.63x | €-198.06 Million | €121.42 Million | ▼ -1559.8% |
| 2016 | -0.10x | €-12.50 Million | €127.18 Million | — |